Could a tiny tablet ease both heavy drinking and PTSD?
NCT ID NCT06335407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a sublingual form of dexmedetomidine (BXCL501) is safe and shows promise for treating alcohol use disorder in people who also have PTSD. Ten heavy drinkers with PTSD will take the drug and be monitored for changes in blood pressure, anxiety, and PTSD symptoms over 28 days. The goal is to gather enough safety and early effectiveness data to plan larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Connecticut Healthcare System
RECRUITINGWest Haven, Connecticut, 06516, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a psychedelic compound help veterans and first responders with PTSD and alcohol use disorder?
- Zapping the brain to fight alcoholism: a new hope?
- Can a simple checklist forecast PTSD after critical illness?
- Rewiring the brain to fight alcohol cravings?
- Can a psychedelic drug help heal trauma? a small trial puts psilocybin to the test
- Can cash rewards and a breathalyzer app help people stay sober?